| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 10 | 128.6x | 17.3x | Bottom tier | |
Growth | 96 | 81.5% | 7.1% | Top tier | |
Quality | 91 | 24.9% | 4.5% | Top tier | |
Safety | 80 | 0.1x | 2.6x | Top tier | |
Capital Return | 18 | 0.00% | 0.06% | Bottom tier | |
Momentum | 93 | 224.4% | -1.6% | Top tier | |
Sentiment | 33 | 4 | 3 | Bottom tier |
The floor: what the company is worth if growth stopped today
89% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Eton Pharmaceuticals develops, acquires, and markets specialized treatments for rare diseases, building its commercial franchises around pediatrics, endocrinology, metabolic diseases, Wilson disease, and pediatric dermatology. Its portfolio includes HEMANGEOL, Increlex, ALKINDI SPRINKLE, KHINDIVI, DESMODA, Galzin, and Carglumic Acid, and it uses the Eton Cares platform to centralize medication dispensing, provide patient support, and reduce out-of-pocket payments. Its growth strategy relies on acquiring rights to commercial products such as HEMANGEOL and IMPAVIDO and licensing late-stage candidates such as ASN-001, then operating them through its existing commercial infrastructure.
Revenue for Q2 FY2026 reached a record 37.6 million dollars, up 99% from 18.9 million dollars in the comparable quarter, while gross profit increased 113% to 25.4 million dollars. The company generated net income of 11.6 million dollars and diluted earnings per share of 0.35 dollars, compared with a net loss of 2.6 million dollars and a loss of 0.10 dollars per share in the comparable period. Adjusted gross profit was 27.4 million dollars at a 73% margin, while adjusted EBITDA reached 16.2 million dollars, or 43% of revenue, compared with approximately 16% in the comparable period.
HEMANGEOL was the largest contributor to growth in Q2 FY2026 and became Eton's largest product, but the company did not disclose revenue for each product separately. Growth also came from Increlex, ALKINDI SPRINKLE, KHINDIVI, Galzin, and Carglumic Acid, while DESMODA was not yet a significant contributor during its first full fiscal quarter on the market. On a trailing-twelve-month basis in EDGAR data, revenue was 105.6 million dollars, gross profit was 61.1 million dollars, and net income was 12.7 million dollars, compared with revenue of 80.0 million dollars and a net loss of 4.6 million dollars in FY2025.
The analyst consensus is "Buy," with an average price target of 66.67 dollars and a target range of 62 to 70 dollars; the average is slightly above the 52-week range high of 66.37 dollars, while the lowest target falls within the annual range. No reported P/E ratio is available, which is important because Eton moved from a net loss of 4.6 million dollars in FY2025 to net income of 12.7 million dollars over the trailing twelve months, so the earnings base used for valuation has not yet stabilized. The relatively narrow target range reflects positive analyst confidence, but the average's proximity to the 52-week range high makes execution against revenue and profit-margin guidance and progress on ASN-001 and HEMANGEOL essential to justifying the valuation.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Eton reported record revenue of 37.6 million dollars, up 99% from the comparable period, with HEMANGEOL the largest contributor to growth. Diluted earnings per share were 0.35 dollars versus an analyst estimate of 0.11 dollars and a loss of 0.10 dollars in the comparable period. Gross profit also increased 113% to 25.4 million dollars, while adjusted EBITDA reached 16.2 million dollars, or 43% of revenue. Increases in Increlex, ALKINDI SPRINKLE, KHINDIVI, Galzin, and Carglumic Acid also contributed to the broader growth base.
The company relaunched HEMANGEOL on May 1, 2026, and it became the largest product in its portfolio and the largest contributor to growth in Q2 FY2026. Approximately 95% of patients had transitioned to the Eton Cares model by the end of June 2026, after which management said it completed the transition of the historical base of approximately 8,000 patients annually. The company estimates net revenue per treatment course at approximately 8,000–10,000 dollars and aims to exceed 10,000 patients annually. The zero-dollar copay program is intended to reduce reliance on adult formulations used off-label.
Automated analysis for informational purposes only — not investment advice.
ASN-001 completed a Phase III trial, but a bioavailability bridging study remained as the final development requirement mentioned on the August 13, 2026 call. The proposed study includes 24 participants over 29 days, and the company estimated its cost at approximately 4 million dollars over 12 months. Eton is targeting submission of the New Drug Application in the second half of 2027, with potential approval and launch in 2028. Management believes the product could become the largest in the portfolio because it targets a segment that could expand the infantile hemangioma franchise market to approximately 20,000–30,000 patients annually.
On August 13, 2026, management raised its revenue guidance to more than 145 million dollars, compared with previous guidance of more than 120 million dollars. It also raised its adjusted EBITDA margin guidance to more than 35% from more than 30%, and expects an adjusted gross profit margin above 70%. Its research and development spending forecast ranges from 10 to 14 million dollars, including the 3 million dollar upfront ASN-001 licensing payment. This guidance also includes the costs of the ASN-001 study and a potential commercial milestone related to ALKINDI SPRINKLE and KHINDIVI.
Eton submitted a prior approval supplement to expand the KHINDIVI label to children under five and expects a decision in the first half of 2027 after the adrenal portfolio surpassed 600 active patients. It plans to submit the Amglidia application by the end of 2026 after receiving Fast Track designation, with potential approval and launch in 2027. ET-700 is being studied in 36 healthy volunteers, and success could lead to a pivotal study in early 2027, while management estimates its potential peak U.S. sales at more than 100 million dollars annually. Eton was also scheduled to begin distributing IMPAVIDO in the United States in late September 2026 through approximately 300 targets for its specialized sales force.
The data shows net insider sales of 18.9 million dollars during the three months ended August 28, 2026. The period included 19 sales and no recorded purchases, making the signal negative from a transaction-direction perspective. However, insider sales may have been prearranged, so they are not sufficient on their own to judge the company's prospects unless the data indicates otherwise. They should be assessed alongside Q2 FY2026 revenue growth of 99%, the increase in revenue guidance to more than 145 million dollars, and the execution risks associated with the ASN-001 and ET-700 programs.